title: Opinions differ by expertise in Mycobacterium avium complex disease.
abstract: BACKGROUND
  Pulmonary Mycobacterium avium complex treatment guidelines rely largely on expert opinion. The extent to which nonexperts agree with recommendations of experts in this clinical area is unknown.
  
  
  OBJECTIVE
  We sought to compare practices and perceptions of prognosis between experts and nonexperts.
  
  
  METHODS
  We surveyed respirologists (Ontario, Canada, "nonexperts") and experts from nontuberculous mycobacterial disease centers of excellence (Canada and United States).
  
  
  RESULTS
  Forty-six Ontario respirologists (29% of 160) and 19 experts (73% of 26) participated. There was agreement between nonexperts and experts regarding disease duration before diagnosis (2 yr), likelihood of spontaneous remission (7-15%), typical duration of treatment (18 mo), first choice of therapy (guideline regimens), a subgroup of patients for whom less-intensive regimens are favored (10% after recurrence), likelihood of recurrence (30%), and median survival (10 yr in most patients). Noted differences were that nonexperts estimated fewer patients with a positive culture had disease (30% vs. 50%, P = 0.02), used intensive guidelines therapy less often in new cases (50% vs. 79%, P = 0.02), and perceived a slightly lower success rate with guidelines therapy (65% vs. 75%, P = 0.047). Response ranges were wider for nonexperts, significantly so for selection of intensive guidelines therapy in new (P = 0.01) and recurrent (P = 0.04) cases.
  
  
  CONCLUSIONS
  Experts and nonexperts agreed on many issues. However, nonexperts perceived lower rates of disease among patients with isolates, tended to use less aggressive treatment approaches, and perceived lower success rates. Significant variability was observed in responses-often wider among nonexperts. Although these results are likely biased by referral, they may identify important areas for targeted education.
authors.affiliation: 1 Division of Respirology, University Health Network and Mount Sinai Hospital, Toronto, Ontario, Canada.
authors.forename: Theodore K
authors.initials: TK
authors.lastname: Marras
authors.forename: D Rebecca
authors.initials: DR
authors.lastname: Prevots
authors.forename: Frances B
authors.initials: FB
authors.lastname: Jamieson
authors.forename: Kevin L
authors.initials: KL
authors.lastname: Winthrop
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002170:Canada; D002983:Clinical Competence; D032921:Consensus; D057210:Delayed Diagnosis; D006801:Humans; D055552:Infectious Disease Medicine / Q000592:standards; D008503:Medical Staff / Q000592:standards; D015270:Mycobacterium avium-intracellulare Infection / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D017410:Practice Guidelines as Topic; D011379:Prognosis; D015272:Pulmonary Medicine / Q000592:standards*; D012008:Recurrence; D012075:Remission, Spontaneous; D015996:Survival Rate; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents